TR200103785T2 - Regulation of excitable tissue function via erythropoietin administered peripherally - Google Patents

Regulation of excitable tissue function via erythropoietin administered peripherally

Info

Publication number
TR200103785T2
TR200103785T2 TR2001/03785T TR200103785T TR200103785T2 TR 200103785 T2 TR200103785 T2 TR 200103785T2 TR 2001/03785 T TR2001/03785 T TR 2001/03785T TR 200103785 T TR200103785 T TR 200103785T TR 200103785 T2 TR200103785 T2 TR 200103785T2
Authority
TR
Turkey
Prior art keywords
tissues
erythropoietin
tissue function
regulation
transport
Prior art date
Application number
TR2001/03785T
Other languages
Turkish (tr)
Inventor
Brines Michael
Cerami Anthony
Cerami Carla
Original Assignee
The Kenneth S. Warren Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Kenneth S. Warren Institute, Inc. filed Critical The Kenneth S. Warren Institute, Inc.
Publication of TR200103785T2 publication Critical patent/TR200103785T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Memelilerde uyarilabilir doku islevini düzenlemek üzere eritropoietin gibi bir eritropoietin reseptörü etkinligi düzenleyicisinin sistemik olarak uygulanmasi yoluyla uyarilabilir doku islevini korumak veya gelistirmek içn yöntemler ve bilesimler temin edilmistir. Uyarilabilir dokular, beyin gibi merkezi nöronal dokular,periferik nöronal dokular, retina ve kalp dokusudur. Uyarilabilr dokularin korunmasi, hipoksiya, felç bozukluklari, nörodejeneratif hastaliklar, hipoglisemi ve nörotoksin zehirlenmelerinin tedavisini temin eder. Islevin gelistirilmesi, ögrenme bellek için kullanislidir. Bulus moleküllerin kan-beyin engeli gibi siki endoteliyal hücre bilesim yerleri engellerinden naklini kolaylastirmak için bilesimler ve yöntemlere de iliskindir; bu nakil molekülün eritropoietin gibi bir eritropoietin reseptörü etkinligi düzenleyicisi ile birlestirilmesi yoluyla gerçeklestirilir.Methods and combinations are provided to protect or enhance the stimulatory tissue function through the systemic application of an erythropoietin receptor activity regulator such as erythropoietin to regulate the inducible tissue function in mammals. Inducible tissues are central neuronal tissues such as the brain, peripheral neuronal tissues, retina and heart tissue. It provides the treatment of adaptable tissues, hypoxia, paralysis disorders, neurodegenerative diseases, hypoglycemia and neurotoxin poisoning. The development of Islevin is useful for learning memory. The invention also relates to compositions and methods to facilitate the transport of molecules from tight endothelial cell junction barriers such as blood-brain barrier; this transport is accomplished by combining the molecule with an erythropoietin receptor activity regulator such as erythropoietin.

TR2001/03785T 1999-04-13 2000-04-13 Regulation of excitable tissue function via erythropoietin administered peripherally TR200103785T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29093899A 1999-04-13 1999-04-13
US54722000A 2000-04-11 2000-04-11

Publications (1)

Publication Number Publication Date
TR200103785T2 true TR200103785T2 (en) 2002-06-21

Family

ID=26966493

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2004/02194T TR200402194T2 (en) 1999-04-13 2000-04-13 Regulation of excitable tissue function via peripherally administered erythropoietin
TR2001/03785T TR200103785T2 (en) 1999-04-13 2000-04-13 Regulation of excitable tissue function via erythropoietin administered peripherally

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2004/02194T TR200402194T2 (en) 1999-04-13 2000-04-13 Regulation of excitable tissue function via peripherally administered erythropoietin

Country Status (21)

Country Link
EP (1) EP1171147A4 (en)
JP (1) JP2003520194A (en)
KR (2) KR101012932B1 (en)
CN (1) CN1607957B (en)
AU (1) AU784550B2 (en)
BG (1) BG65353B1 (en)
BR (1) BR0009737A (en)
CA (1) CA2383940A1 (en)
CR (1) CR6501A (en)
CZ (1) CZ20013695A3 (en)
EA (1) EA004766B1 (en)
HU (1) HUP0201598A3 (en)
IL (2) IL145895A0 (en)
IS (1) IS6104A (en)
MX (1) MXPA01010177A (en)
NO (1) NO20014991L (en)
NZ (4) NZ545478A (en)
PL (1) PL352223A1 (en)
SK (1) SK14412001A3 (en)
TR (2) TR200402194T2 (en)
WO (1) WO2000061164A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7304031B2 (en) 2001-10-29 2007-12-04 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
DE60140054D1 (en) 2000-06-30 2009-11-12 Tokyo Metropolitan Inst Of Ger PREVENTIVA AND THERAPEUTICS FOR DEMYELINISATION ASSOCIATED DISEASES
DE10043457A1 (en) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (en) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
PT1471871E (en) * 2001-02-02 2007-06-05 Ortho Mcneil Pharm Inc Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
AU2002351444B2 (en) 2001-12-07 2008-02-21 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
ATE359087T1 (en) 2002-01-09 2007-05-15 Crucell Holland Bv USE OF ERYTHROPOIETIN TO TREAT OR PREVENT HEART FAILURE
AU2002307635A1 (en) * 2002-04-19 2003-11-03 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
US20040122216A1 (en) * 2002-07-01 2004-06-24 Jacob Nielsen Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE10234192B4 (en) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Use of erythropoietin
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
NZ542092A (en) * 2003-03-27 2008-04-30 Janssen Pharmaceutica Nv Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
BRPI0409895B8 (en) 2003-05-09 2021-05-25 Crucell Holland Bv method of culturing cells derived from per.c6 cells capable of growing in suspension to increase the product yield of said cells
DE102004063927A1 (en) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage
AT500929B1 (en) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw PHARMACEUTICAL PREPARATION CONTAINING ERYTHROPOIETIN
MX364100B (en) 2005-08-05 2019-04-12 Araim Pharmaceuticals Inc Tissue protective peptides and uses thereof.
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
DE102006004008A1 (en) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
CN101062407A (en) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
US8133860B2 (en) * 2006-07-20 2012-03-13 Rosalind Franklin University Of Medicine And Science Facilitation of resuscitation from cardiac arrest by erythropoietin
JP2010515736A (en) * 2007-01-10 2010-05-13 エジソン ファーマシューティカルズ， インコーポレイテッド Treatment of respiratory chain disorders with compounds having erythropoietin activity or thrombopoietin activity
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
KR20200075044A (en) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2519695C2 (en) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Medication for treating attention deficit disorder and method of treating attention deficit disorder
CN111066727B (en) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 Method for constructing mouse model of action mechanism in permeability of hypoxic blood testis barrier

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
DE19857609A1 (en) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia

Also Published As

Publication number Publication date
CR6501A (en) 2004-04-15
HUP0201598A2 (en) 2002-09-28
CN1607957B (en) 2012-10-10
JP2003520194A (en) 2003-07-02
EA200101073A1 (en) 2002-10-31
WO2000061164A1 (en) 2000-10-19
NZ533098A (en) 2006-04-28
NO20014991L (en) 2001-11-15
NO20014991D0 (en) 2001-10-12
HUP0201598A3 (en) 2002-10-28
CN1607957A (en) 2005-04-20
KR101012932B1 (en) 2011-02-08
NZ545478A (en) 2008-04-30
EP1171147A4 (en) 2003-05-14
PL352223A1 (en) 2003-08-11
KR100883232B1 (en) 2009-02-10
IL145895A (en) 2010-05-31
NZ514690A (en) 2004-07-30
IL145895A0 (en) 2002-07-25
CZ20013695A3 (en) 2002-02-13
IS6104A (en) 2001-10-11
KR20070094997A (en) 2007-09-27
BR0009737A (en) 2003-01-14
MXPA01010177A (en) 2004-09-10
TR200402194T2 (en) 2004-10-21
AU4348700A (en) 2000-11-14
EP1171147A1 (en) 2002-01-16
SK14412001A3 (en) 2002-03-05
BG106058A (en) 2002-12-29
CA2383940A1 (en) 2000-10-19
EA004766B1 (en) 2004-08-26
AU784550B2 (en) 2006-05-04
BG65353B1 (en) 2008-03-31
NZ560696A (en) 2010-03-26
KR20020000874A (en) 2002-01-05

Similar Documents

Publication Publication Date Title
TR200103785T2 (en) Regulation of excitable tissue function via erythropoietin administered peripherally
Frazzini et al. Oxidative stress and brain aging: is zinc the link?
Fisher Redox signaling across cell membranes
CY1121447T1 (en) COMPOSITIONS FOR INCREASING TELEVISION ACTIVITY
Giuliani et al. Low infra red laser light irradiation on cultured neural cells: effects on mitochondria and cell viability after oxidative stress
ATE96679T1 (en) MACROMOLECULAR PLATINUM ANTITUMORS COMPOUNDS.
Man et al. Role of nitric oxide in regulating epidermal permeability barrier function
ATE244572T1 (en) PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG ADMINISTRATION
BR0315688A (en) Compounds, pharmaceutical compositions and their uses in the treatment or prevention of diseases or conditions of metabolic cell proliferation
BR9611748A (en) Use of a neurotrophic factor protein product derived from glial cell lineage
EP3118218A3 (en) Fusion proteins for blood-brain barrier delivery
US10568819B2 (en) Skin enhancing compositions and methods
IL172613A0 (en) Pan-kir2dl nk-receptor antibodies and their use in diagnostic and therapy
DE69709458D1 (en) USE OF THE GLIAL, NEUROTROPHIC FACTOR (GDNF) FOR TREATING HEARING DISORDERS
DE69630325D1 (en) Nerve endings for mammalian eyes using potassium channel blockers
DE602005010047D1 (en) NERVE GROWTH FACTOR SEZERNATING HUMAN THERAPEUTIC CELLS
Arul et al. Biotinylated GHK peptide incorporated collagenous matrix: A novel biomaterial for dermal wound healing in rats
BRPI0502628A (en) sunscreen composition
UY26464A1 (en) "COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND ELONGATION OF NEURONS"
BR9608789A (en) Tetralin compounds with mdr activity
ATE413179T1 (en) THERAPEUTIC USES OF STEROIDS IN BLOOD CELL DEFICIENCY CONDITIONS
MX9602973A (en) Use of bradyquinine antagonist in a cosmetic, pharmaceutical or dermatological composition, and composition obtained therefrom.
EP3329913A1 (en) Composition for inhibiting formation of snare complex, containing myricetin derivatives
JP2003137783A (en) Composition and method for using pyridinium derivative for cosmetic and therapeutic application
ATE340785T1 (en) 2-PHENYLAMINO-4-TRIFLUOROMETHYL-5-(BENZYL OR PYRIDINE-4-YLMETHYL)CARBAMOYLPYRIMIDINE DERIVATIVES AS SELECTIVE CB2 CANNABINOID RECEPTOR MODULATORS